Na v 1.5, the pore forming a-subunit of the voltage-dependent cardiac Na + channel, is an integral membrane protein involved in the initiation and conduction of action potentials. Mutations in the gene-encoding Na v 1.5, SCN5A, have been associated with a variety of arrhythmic disorders, including long QT, Brugada, and sick sinus syndromes as well as progressive cardiac conduction defect and atrial standstill. Moreover, alterations in the Na v 1.5 expression level and/or sodium current density have been frequently noticed in acquired cardiac disorders, such as heart failure. The molecular mechanisms underlying these alterations are poorly understood, but are considered essential for conception of arrhythmogenesis and the development of therapeutic strategies for prevention or treatment of arrhythmias. The unravelling of such mechanisms requires critical molecular insight into the biology of Na v 1.5 expression and function. Therefore, the aim of this review is to provide an up-to-date account of molecular determinants of normal Na v 1.5 expression and function. The parts of the Na v 1.5 life cycle that are discussed include (i) regulatory aspects of the SCN5A gene and transcript structure, (ii) the nature, molecular determinants, and functional consequences of Na v 1.5 post-translational modifications, and (iii) the role of Na v 1.5 interacting proteins in cellular trafficking. The reviewed studies have provided valuable information on how the Na v 1.5 expression level, localization, and biophysical properties are regulated, but also revealed that our understanding of the underlying mechanisms is still limited.
Introduction
Voltage-gated sodium channels are integral membrane proteins, involved in the generation and propagation of action potentials. In mammals, SCN1A-SCN11A are the genes of a family of nine functionally expressed voltage-gated sodium channels that are more than 50% homologous in amino acid sequence. 1 The human SCN5A gene, located on chromosome 3p21, encodes the major cardiac voltagegated sodium channel a-subunit Na v 1.5. 2 Na v 1.5 is not exclusively expressed in heart; however, since it has also been detected in the brain and gastrointestinal smooth muscle; moreover, its expression and functionality in promoting invasiveness has also been shown in, for example, breast cancer cells. 1, 3, 4 The Na v 1.5 a-subunit is the pore-forming component of the cardiac sodium channel and contains four homologous transmembrane domains DI-DIV ( Figure 1 ). These domains are linked by intracellular loops (IDI-II, IDII-III, and IDIII-IV). Each domain consists of six transmembrane segments (S1-S6). S4 is positively charged and is involved in voltage-dependent activation of the channel, while the inactivation gate is formed and stabilized by complexation of the intracellular IDIII-IV loop and the C-terminal domain. 5 The actual Na + -conducting channel pore is lined by the S6 segments and the pore loops between S5 and S6 in each domain. 6 Although Na v 1.5 a-subunits can act as voltage-gated sodium channels in their own right, in vivo the Na + channel is part of a large multiprotein complex. Specific cytoskeletal, regulatory, trafficking, cell adhesion, and gap junction proteins have been found in close association with Na v 1.5, some of which alter the cell biological and/or biophysical properties of the channel (reviewed in reference, 7 schematically illustrated in Figure 1 and specified in Table 1 ).
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Over the past 15 years, numerous mutations in SCN5A have been associated with various rare arrhythmia syndromes, such as congenital Long QT syndrome type 3 (LQTS3), Brugada syndrome (BrS), progressive cardiac conduction defect (or Lenègre-Lev disease), sick sinus syndrome, and atrial standstill. 6, 48 Besides increasing our insight in Na v 1.5 biology and regulation, such studies also correlated altered action potential morphology and increased arrhythmia vulnerability with changes in the Na v 1.5 expression level and/or sodium current (I Na ) density. Such changes have been frequently reported in more common cardiac diseases such as heart failure, 49 -51 but relatively little is known regarding the underlying mechanisms. Understanding the molecular basis of Na v 1.5 expression and function may yield critical molecular insight into arrhythmogenesis and may suggest novel therapeutic strategies for prevention or treatment of cardiac arrhythmias. The aim of this review is, therefore, to provide an updated account of the biology of Na v 1.5 expression.
Cardiac sodium channel gene and transcript structure
In general, Na v 1.5 RNA is derived from 28 different exons. Exons 2-28 contain the protein-coding sequence (shaded boxes in Figure 2 ).
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Exon 1 and part of exon 2 further encode the 5 ′ -untranslated region (5 ′ -UTR), whereas exon 28 also contains the 3 ′ -UTR. Multiple Na v 1.5 RNA variants have been detected in the mammalian heart, most of which are generated by alternative splicing and apparently evolutionary conserved mechanisms. 52 In both human ( Figure 2A ) and mouse ( Figure 2B ) heart, two prominently expressed RNA variants have been detected encoding the fulllength Na v 1.5 protein, yet differing in the length of their 3 ′ -UTR (28A short and long variants). For human, three other, relatively minor expressed, variants were also identified, resulting from the splicing of exon 27 to alternative exons 28 (28B, 28C, and 28D), which have not been detected in other mammals. 53, 54 Furthermore, in human and mouse heart, respectively, four and three distinct splicing variants have been reported, which differed in the composition of their 5 ′ -noncoding sequence due to the splicing of alternative exons 1 (denoted 1A -1D) to exon 2. It should be noted that human exon 1A proved to be homologous to mouse exon 1A but that, despite their similar notation, the human exons 1B and 1C were not homologous to the corresponding mouse exons. 53, 55 In both human and rodent hearts, variation has also been observed in the way exon 17 was spliced to the subsequent exon. Differential usage of a splice acceptor site at the intron 17/exon 18 junction resulted in two prominent RNA variants, named Q1077del and Q1077/Na v 1.5c (occurrence ratio 65:35%, respectively), of which the Q1077/Na v 1.5c variant possesses an additional CAG triplet producing a Na v 1.5 protein with an extra glutamine residue in the IDII-III linker region. 56, 57 Yet another variant, Na v 1.5d, was identified in both embryonic and adult human hearts, and lacked in-frame 120 bp within exon 17 resulting in a Na v 1.5 protein lacking 40 amino acids in the second intracellular loop (IDII -III). 58 Exon skipping has also been reported as a mechanism to create Na v 1.5 RNA variety in the heart. RNA isoforms lacking in-frame either exon 18 (hNbR1-2/Na v 1.5a in Figure 2A and mH1-2/Na v 1.5a in Figure 2B ), 59,60 both exons 17 and 18 (mH1-3/Na v 1.5b in Figure 2B ), 60 or exon 24-derived sequences (Na v 1.5f in both Figures 2A and B ) 61, 62 have been identified, thus all encoding for shorter versions of Na v 1.5. For neonatal, but not adult, hearts a SCN5A splice variant has also been reported in which the regular exon 6 was replaced by an alternative exon 6A (Figure 2 ; designated as neonatal/hNbR1/Na v 1.5e). 59,61 -63 This 'neonatal' splice form varies at 31 nucleotide positions with the exon 6 containing 'adult' form, resulting in 7 amino acid differences in the transition region between S3 and S4 of DI. In addition to alternatively spliced transcripts, differences in amino acid composition of the Na v 1.5 protein have also been observed. Five different protein sequences, for example, for the human Na v 1.5 channel (designated SCN5A/Q1077, hH1, hH1a, hH1b, and hH1c/ Q1077del) have been identified varying in 5 out of 2016 amino acids (inset box in Figure 2A) . 56,64 -66 Of these, hH1, hH1a, and hH1b represent rare variants. 56 Since such amino acid variations, but also the nature of the Na v 1.5 variant applied, are known to affect the function of wild-type and mutant reference channels (Table 2) , 66,67 the choice of background sequence is important for expressional and functional studies of the SCN5A gene.
Regulation of Na v 1.5 expression
The life cycle of Na v 1.5 starts with the transcription of its gene, followed by RNA processing and protein synthesis at the endoplasmic reticulum (ER), where it is inserted into the membrane. From the ER, Na v 1.5 follows the secretory pathway until it reaches the sarcolemma, where it exerts its functional role. Immunocytochemical analysis of Na v 1.5 expression suggested preferential localization in intercalated disc regions, 68 -70 although its presence in lateral membranes and the T-tubular system has also been recognized. 71 -73 Along the way Na v 1.5 is post-translationally modified, anchored to the cytoskeleton, putatively stored in subcellular compartments, and assembled into a multiprotein complex. Eventually, Na v 1.5 is endocytosed from its membrane position and degraded. Although presently not much is known about the time scale of these events, the functional half-life of Na v 1.5 sodium channels has been estimated in adult dog cardiomyocytes to be in the order of 32 -36 h. 74 In this section, our current understanding of the molecular mechanisms determining and regulating functional Na v 1.5 expression and trafficking will be discussed. 
Transcriptional regulation of SCN5A/ Scn5a
Na v 1.5 displays a tissue-restricted expression pattern, which likely originates at the transcriptional level. For the human SCN5A gene, standard in vitro promoter/reporter analyses in cell lines have implicated sequences associated with exons 1A (designated promoter P1), 1B (P2), and 1C/1D (P3) in its transcriptional regulation ( Figure 2A) . 55, 75 However, the precise nature of the transcription factors and their respective binding sites have not been determined yet. More importantly, involvement of these designated sequences in in vivo SCN5A gene regulation and expression awaits confirmation. Recently, Atack et al. 76 elegantly associated deletion of a 435 bp sequence from intron 1 of mice, in which expression of murine Scn5a was replaced by human SCN5A, with increased Na v 1.5 transcript, protein, and sodium current levels as well as with shorter QRS durations. The repressive capacity of this 435 bp fragment on human SCN5A promoter P1 activity was further confirmed in vitro in isolated cardiomyocytes and assigned to the presence of an E-box motif. For the mouse Scn5a gene, promoter/reporter analyses in cardiac and skeletal muscle cell lines identified cardiac-specific Biology of Na v 1.5 expression enhancer elements associated with exons 1A and 1C, each of which was preceded by a repressive element. 53 Interestingly, the relative gene position of the repressive element associated with mouse exon 1C correlates with that of the earlier-mentioned human 435 bp repressive element. Recently, it was also shown that angiotensin II-induced reduction in sodium current and Scn5a RNA expression in neonatal ventricular cardiomyocytes were mediated by a NF-kB site located in exon 1C. 77 Although these studies provide an essential first characterization of the SCN5A/Scn5a regulatory sequences, we are still far from understanding the molecular basis of tissue-specific Na v 1.5 expression.
Consequences of SCN5A/Scn5a transcript variation
Alternative promoter usage and splicing of the SCN5A/Scn5a gene underlie the multiple transcripts encoding Na v 1.5 identified in the heart. Several studies demonstrated that not all of these transcripts translate into the Na v 1.5 protein with equal efficiency or functional properties (summarized in Table 2 ). For instance, the presence of an upstream open reading frame in the human SCN5A transcript containing exon 1D-derived sequences ( Figure 2A ) almost completely abolished translation of Na v 1.5. 55 The 28C and 28D variants, when expressed in HEK293 cells, did not generate significant sodium current or protein by themselves, but reduced the sodium current produced by the normal full-length 28A variant, presumably by downregulating its RNA level. 54 The Q1077 variants tended to produce smaller sodium currents in HEK293 cells than the Q1077del variant, a phenomenon emphasized by the presence of the common H558R polymorphism. 56 Electrophysiological comparison of the 'neonatal'
and 'adult' isoforms in EBNA-293 cells revealed altered channel kinetics and prolonged current (increasing the Na + influx) for the 'neonatal' channel. 78 Finally, upon expression in HEK293 cells, the hNa v 1.5f and mH1-3 variants proved to be non-functional. 52, 60 Thus, (patho)physiologically induced alterations in the relative occurrence of Na v 1.5 transcripts potentially will affect cardiac sodium channel expression and function. Indeed, Shang et al. 54 recently associated the reduction in sodium channel protein observed in human heart failure with a relative increase in expression of the SCN5A 28C and 28D RNA variants. 
Denotations used: V 1/2 (in)act., half-maximal voltage of (in)activation; speed act., time to peak of activating Na + -currents; speed inact., time constant(s) of decay of inactivating Na + -currents; recovery time inact., time constant(s) of recovery from steady-state inactivation; △, deleted; ↔, unchanged; , increased; , decreased; + , depolarized shift; 2, hyperpolarized shift; h, human; m, mouse; nd, not determined.
Glycosylation
The Na v 1.5 protein harbours in its extracellular domain multiple evolutionary conserved amino acid motifs for N-glycosylation. Although the precise molecular composition of the N-glycans in cardiomyocytes and their attachment sites have not been determined yet, their presence in cardiac Na v 1.5 and impact on channel gating have been recognized. By using subtype-specific antibodies and Nglycanase treatment, rat heart H1 (rH1, Figure 2B ) was shown to be a sialoglycoprotein with an estimated carbohydrate mass of 5%. 79 The functional role of Na v 1.5 glycosylation, and in particular sialylation, has been studied in several ways. Zhang et al. 80 expressed the human H1a isoform (Figure 2A) in HEK293 cells to demonstrate that pre-treatment of cells with N-glycosylation inhibitors or removal of sialic acid by neuraminidase caused depolarizing shifts in both steady state activation and inactivation. A similar depolarizing shift in sodium channel gating was observed in adult rat ventricular myocytes upon neuraminidase treatment. 81 However, since enzymatic treatment was performed on whole cell preparations, this effect could not be completely contributed to Na v 1.5. Sodium currents with altered voltage dependencies of (in)activation were also measured in mouse hearts lacking the muscle LIM protein, which were correlated with sialic acid-deficiency of the Na + channel protein. Both altered gating characteristics and a reduction in Na v 1.5 protein expression appeared to contribute to the arrhythmogenic phenotype in this model of heart failure. 82 Interestingly, changes in the sialylation status of Na v 1.5 were not for every expression system correlated with altered channel properties. Bennett 83 compared the voltagedependent gating parameters of the human Na v 1.5 H1 isoform ( Figure 2A ) in two CHO cell lines, the fully sialylating Pro5 and the sialylation-deficient Lec2 cell line, to demonstrate that gating was unaffected. This discrepancy in results is not easily explained, but may be related to, for example, differential N-glycosylation between the expression systems studied or the particular Na v 1.5 variant investigated.
A microarray-based comparison of glycogene (i.e. glycosyltransferases, glycosidases, and sugar nucleotide synthesis/transporter genes) expression between neonatal and adult atrial/ventricular myocytes revealed chamber-specific and developmental differences. Consequently, the N-glycan profiles of different cardiomyocyte subtypes were markedly variable. Expression of the polysialyltransferase ST8sia2, for instance, was restricted to the neonatal atrium. Absence of this transferase altered gating of voltage-dependent Na + channels in neonatal atrial myocytes consistent with observed changes in action potential morphology. 84 In cardiac disease, electrical remodelling is usually ascribed to altered expression and distribution of ion channel proteins such as Na v 1.5. This study implicates aberrant expression of glycogenes, and in particular those involved in sialylation, also as modulator of voltage-dependent sodium channelmediated electrical signalling. Initially, differential effects on cardiac I Na were observed upon stimulation of the b-adrenergic receptor/adenylyl cyclase/cAMP/PKA pathway, most likely due to technical difficulties to measure the current. 85 More recently, b-adrenergic pathway stimulation (via e.g.
Phosphorylation and the role of Ca
receptor agonists or cAMP analogs) in cardiomyocytes or cells heterologously expressing rH1 or hH1 (Figure 2 ) consistently resulted in an increased peak I Na . 86 -91 On the basis of induction experiments with b-adrenergic receptor agonists or cAMP analogs alone, it is not justified to conclude that the observed I Na modulation is the result of phosphorylation of Na v 1.5 by PKA itself. Nevertheless, phosphorylation of immunoprecipitated rH1 by purified PKA has been demonstrated on S526 and S529 in IDI-II (Figure 1) . 92 Furthermore, it has been shown that b-adrenergic stimulation of rat ventricular myocytes by isoproterenol (ISO) in the presence of a PKA inhibitor (PKI) enhanced I Na by 31%, in contrast to the 68% increase observed with ISO alone. 88 Collectively, these studies suggest a direct role for PKA in modulation of cardiac I Na . Besides phosphorylation sites for PKA, the IDI -II linker region also contains three putative RXR-type ER retention motifs, which upon elimination abolished the cAMP-mediated increase in I Na . 90 Resident ER chaperone proteins may bind to such motifs thereby inhibiting export from the ER and trafficking to the cell surface. As demonstrated for the NMDA receptor, phosphorylation may relieve such ER retention. 93 It is therefore possible that these retention signals mediate initial retainment of Na v 1.5 channels in the ER, and that phosphorylation of Na v 1.5 by PKA masks the retention signals permitting export from the ER and enhancing expression at the cell surface. In this regard, it is interesting that a GFP-tagged version of Na v 1.5 in HEK293 cells is abundantly present in two intracellular pools, one in the ER and the other just beneath the cell surface. cAMP-induced activation of PKA increased peak I Na in these cells, which was correlated with a redistribution of Na v 1.5-GFP expression from these pools to the cell surface. 91, 94 It is therefore plausible that PKA-dependent phosphorylation of Na + channels facilitates transport from intracellular storage compartments, such as the ER, to the cell surface.
Protein kinase C (PKC)
The involvement of PKC in modulation of the cardiac I Na has been primarily studied in either native cardiac myocytes or cells heterologously expressing Na v 1.5 by investigating the effect of specific PKC activators or inhibitors. The effect most frequently reported in relation to PKC activation concerned a reduction in I Na amplitude. 95 -101 However, no change 102 or an increase in peak I Na 103, 104 have also been associated with PKC activation. In some, but not all, studies alterations in Na v 1.5 biophysical properties were noticed, including hyperpolarizing shifts in steady-state activation 103 and inactivation, 96 ,97,103 a depolarizing shift in steady-state inactivation and enhanced recovery from inactivation. 102 The molecular events underlying PKC activation and subsequent modulation of the cardiac I Na are not completely understood. Functional studies with wild-type and mutated forms of Na v 1.5 suggested that PKC exerts its effect through phosphorylation of S1503 in human or S1505 in rat H1. 97, 98 In this respect, it is interesting to note that mutation of this serine has no effect on cAMP-mediated modulation of I Na in Xenopus laevis oocytes, in contrast to mutation of the homologous serine in the neuronal sodium channel isoform, which suggests isoform-specific modulation of these sodium channels by PKC. 105 Regarding PKC isoforms involved in I Na modulation, controversial results have been obtained. Employing isoform-specific activators or inhibitors, it was observed that conventional rather than novel PKCs mediated the PKC-dependent effect on hH1-derived I Na , 99 Na v 1.5 that the decrease in I Na and Na v 1.5 cell surface expression, observed upon co-expression with the GPD1L SIDS E83K and BrS A280V mutants, was dependent on PKC-mediated phosphorylation of S1503. Moreover, they showed close association between wildtype Na v 1.5 and GPD1L in these cells ( Figure 1 and Table 1 ). Independently, Liu et al. 101 showed in HEK293 cells expressing Na v 1.5 and in rat neonatal cardiomyocytes that the reduction in I Na by the GPD1L A280V mutant could be mimicked by application of NADH or a PKC activator, and antagonized by NAD + administration or a PKC inhibitor. Although these reports provide for more insight into the molecular mechanisms underlying PKC-mediated I Na modulation, additional studies are necessary to fully understand this phenomenon. CaM and CaMKII caused a depolarizing shift in sodium channel inactivation and decreased entry into slow inactivation, but that only CaMKII was able to increase the late I Na and recovery from inactivation. The latter CaMKII-mediated effects were consistent with findings obtained in rat ventricular myocytes employing CaMKII inhibitors (KN93, AIP). 29 However, a study on the effects of CaMKIId c overexpression on I Na in ventricular cardiomyocytes presented both conflicting (negative shift in steady-state inactivation, slowed recovery from inactivation) and supportive evidence (increased late I Na ). 28 Interestingly, the stimulatory effect of CaMKIId on late I Na was recently suggested to be mediated, at least in part, by reactive oxygen species. 111 The involvement of CaMKII in Na v 1.5 regulation has been further substantiated by demonstrating colocalization and co-immunoprecipitation of Na v 1.5 with CaMKII, and CaMKIIdependent phosphorylation of the Na v 1.5 IDI-II linker (in particular S571) and C-terminal regions. 28 -30,106,112 Remarkably, whereas
CaMKII-dependent phosphorylation of Na v 1.5 appears to increase late I Na and intracellular Na + concentration, 28 recent evidence suggests that the reciprocal process (i.e. CaMKII activation and subsequent Na v 1.5 phosphorylation due to a Na v 1.5-dependent increase in intracellular Na + concentration) also may occur. 30 Altogether, the inconsistencies in data are not easily explained but may be the result of, for example, differences in species, expression systems, (electrophysiological) procedures, or protein (e.g. Na v 1.5, CaMKII) isoforms applied between the studies, or may also reflect the existence of more than one Ca 2+ -dependent regulatory mechanism for Na v 1.5. 106, 113 Nevertheless, the combined results clearly have defined Ca 2+ , CaM, and CaMKII as regulators of Na v 1.5, but also show the need for additional studies to elucidate their precise mode(s) of action.
Tyrosine phosphorylation
Regulation of cardiac I Na by tyrosine phosphorylation has been addressed in only a limited number of studies. Blocking of protein tyrosine kinases in rabbit ventricular myocytes inhibited I Na by shifting the voltage for steady-state inactivation to more hyperpolarized potentials. 114 In this study, however, the findings were not validated by measuring the phosphotyrosine levels of the cardiac sodium channel so it is possible that the effects were caused indirectly. Stimulation of the epidermal growth factor (EGF) receptor, a receptor protein tyrosine kinase, by EGF in guinea pig ventricular myocytes enhanced I Na , the effect of which was antagonized by a selective EGF receptor kinase inhibitor and potentiated by a protein tyrosine phosphatase inhibitor. 115 Both the EGF-and tyrosine phosphatase inhibitormediated enhancement in I Na were correlated with increased tyrosine phosphorylation levels of cardiac sodium channels. Recent studies of heterologously expressed Na v 1.5 implicated the Src family tyrosine kinase Fyn 116 and the tyrosine phosphatase PTPH1 20 in Na v 1.5 phosphorylation and dephosphorylation, respectively. Co-expression with constitutively active Fyn in HEK293 cells shifted steady-state Na v 1.5 inactivation towards more depolarized potentials, a feature which was opposed in the same expression system by co-expression with PTPH1. Tyrosine residue Y1495, located in IDIII-IV, was validated as the preferred phosphorylation site for Fyn in human Na v 1.5 ( Figure 1) . Interestingly, recently it was demonstrated that this tyrosine residue is involved in anchoring of Ca 2+ /CaM to the Na v 1.5 inactivation gate and suggested that phosphorylation of Y1495 would interfere with this process. 25 The target tyrosine-phosphate for PTPH1 in Na v 1.5 has not been determined yet, although interaction with the C-terminal Na v 1.5 PDZ-domain binding motif appears to be required for its activity. Altogether, these results suggest that the level of tyrosine phosphorylation, as controlled by the balance between the activities of tyrosine kinases (e.g. Fyn) and phosphatases (e.g. PTPH1), regulates I Na mainly through modulation of Na v 1.5 inactivation characteristics.
Regulation by the stimulatory G protein subunit-a (G s a)
Induction studies with the b-adrenergic receptor agonist ISO on cardiomyocytes have demonstrated the presence of both indirect (PKA-dependent) and direct (PKA-independent) mechanisms for modulation of I Na . 36, 88, 117 Consistent stimulation of cardiomyocytes with ISO in the presence of a PKI discriminated the PKA independent from the PKA-mediated effect. G s a, and in particular a 10 residue peptide sequence (amino acids 33-42) therein, appears to be the key mediator for the PKA-independent response since its intracellular administration was sufficient to mimic the PKA-independent increase in I Na . Furthermore, functional measurements indicated that the increase in I Na was not due to alterations in channel inactivation or activation kinetics, but the result of an increased number of functional channels at the cell surface. 88 Since caveolin-3 antibodies were able to inhibit the G s a-dependent increase in sodium current this suggested that caveolae, plasma membrane invaginations, act as storage reservoirs from which rapidly Na + channels can be recruited. This was further substantiated by demonstrating an association between sodium channels, G s a and caveolin-3 in caveolin-enriched membrane fractions by both immunofluorescence and immunoprecipitation techniques. 36 It is now believed that the binding of G s a to caveolin-3 results in unlocking caveolae, thereby making the caveolar-associated Na + channels available and thus increasing I Na . 117 
Molecular factors involved in Na v 1.5 trafficking
Recently, considerable insight has been gained in molecular events involved in Na v 1.5 trafficking, among which the already discussed recruitment of Na v 1.5 channels from intracellular storage compartments in response to b-adrenergic receptor stimulation via both PKAdependent and -independent mechanisms. Characterization of the cardiac Na v 1.5 multiprotein complex revealed roles for a number of proteins (ankyrin-G, syntrophin, SAP97, plakophilin-2, a-actinin-2, Nedd4-2) in trafficking of Na v 1.5 ( Table 1 ). These will be discussed next. One of the most intriguing questions is how Na v 1.5 is delivered to and retained in both the lateral cardiomyocyte plasma membrane and intercalated disc, where it is preferentially localized. Several findings have implicated ankyrin-G, member of a family of membrane adaptor proteins, in these processes: 14 -16,118 (i) ankyrin-G is primarily expressed at the intercalated disc membrane and T tubules, where it colocalizes with Na v 1.5.
(ii) Ankyrin-G and Na v 1.5 co-immunoprecipitate from cardiac tissue. (iii) Proper Na v 1.5 localization in cardiomyocytes is dependent on the direct interaction of ankyrin-G with the IDII -III loop of Na v 1.5 ( Figure 1) ; mutations in either ankyrin-G or Na v 1.5 interfering with this interaction affect Na v 1.5 localization, expression, and function. (iv) The human E1053K Na v 1.5 mutation, associated with BrS, blocks binding to ankyrin-G and interferes with proper Na v 1.5 surface expression in cardiomyocytes. In addition to ankyrin-G, syntrophin and SAP97 have also been shown to interact with Na v 1.5 and regulate its trafficking to the cardiomyocyte cell surface. The interaction with syntrophin, mediated by the last three amino acid residues (SIV) of Na v 1.5 ( Figure 1 ), appears to be essential for expression at the lateral membrane, whereas SAP97 appears to mediate Na v 1.5 expression at the intercalated disc. 8 -13 The functional importance of the syntrophin/Na v 1.5 interaction has been emphasized by the observed association between mutations in the gene encoding a1-syntrophin (SNTA1), detected in patients with LQTS and SIDS, and increased peak and late I Na . This Na v 1.5 gain-of-function phenotype was for the SNTA1-A390V, -S287R, -T372M and -G460S mutations mediated by neuronal nitric oxide synthetase (nNOS) and dependent on a protein complex consisting of a1-syntrophin, nNOS, and plasma membrane Ca-ATPase subtype 4b (PMCa4b), an inhibitor of nNOS, in which Na v 1.5 also participates. Disruption of this complex by mutations in SNTA1 is believed to release nNOS inhibition leading to Na v 1.5 S-nitrosylation and increased I Na (peak and late), thus providing a first molecular clue for the earlier observed regulation of I Na by nitric oxide (NO). 10, 119, 120 For SAP97, as yet no genetic variants have been identified associated with human cardiac disease, but it can be anticipated that such mutations will have an impact on Na v 1.5 localization and/or function. Besides SAP97, other proteins mainly expressed at the intercalated discs (plakophilin-2, Cx43, N-cadherin, MOG1) participate in the Na v 1.5 multiprotein complex. 17, 35, 38 For both plakophilin-2 and MOG1, the association with Na v 1.5 in cardiomyocytes has been confirmed by colocalization and co-immunoprecipitation experiments whereas their presence was required for full I Na expression, indicating a regulatory role for sodium channel function. Whether the close association between Na v 1.5 and either plakophilin-2, Cx43, N-cadherin, or MOG1 is essential for targeting or retaining Na v 1.5 at the intercalated disc remains to be determined. Alternatively, anchoring of Na v 1.5 to cardiac membrane domains along sarcomeric Z lines has been suggested to be mediated by a-actinin-2, an adaptor protein generally linking transmembrane proteins to actin filaments. 42 a-Actinin-2 proved to be a new interacting partner of Na v 1.5 (mediated by the cytoplasmic IDIII-IV loop, Figure 1 ) and, in a heterologous expression system, influenced the level of Na v 1.5 expression at the cell membrane. Collectively, the above-mentioned studies have provided valuable insight into Na v 1.5 targeting and/or anchoring at specific subdomains of the cardiomyocyte cell membrane, which can be further explored to elucidate the distinct role of each protein in these processes. Another interesting question concerns how Na v 1.5 membrane turnover is regulated. Observations by Abriel and coworkers 31 -33 indicated a role for the ubiquitin-protein ligase Nedd4-2 in this process. Co-expression of Nedd4 with Na v 1.5 in heterologous expression systems resulted in reduced peak I Na , which was correlated with decreased cell membrane channel density. In addition, an interaction between Nedd4-2 and Na v 1.5 in heart extracts was demonstrated; a phenomenon dependent on the integrity of a PY-motif in the C-terminal tail of Na v 1.5 ( Figure 1 ). Nedd4-2-dependent ubiquitination of Na v 1.5 was also observed. Altogether, these results suggest a role for Nedd4-2 in regulating Na v 1.5 channel density at the cell membrane, but the precise mode of action remains to be resolved.
Role of b-subunits in human Na v 1.5 regulation
The Na v 1 b-subunit gene family comprises four members, SCN1B -SCN4B, which are all expressed in the heart (b1-b4 subunits, respectively). These b-subunits have been reported to associate with Na v 1.5 38,43 -47 and modulate Na v 1.5 cell surface expression and channel gating. 7, 121 However, current data sometimes are conflicting, possibly due to differences in experimental conditions or, more importantly, species studied. Species-specific variations in expression of different voltage-dependent sodium channel a-subunits may affect the cardiac sodium current. In mouse heart, for instance, RNA expression for Na v 1.1 -Na v 1.7 and protein expression for Na v 1.1, Na v 1.3, Na v 1.5, and Na v 1.6 has been reported. 69, 122 In contrast, transcripts other than for Na v 1.5 seem hardly present in Biology of Na v 1.5 expression human heart, where the SCN5A transcript appears to be predominant. 123 Since b1-b4 also co-localize with the other sodium channel a-subunits in various compartments in mouse heart, 69 the mouse may not be an ideal model to study the (patho)physiology and regulation of the cardiac sodium current. Considering the above and two recent reviews on this topic, 7,121 the next paragraph summarizes only the regulation of human Na v 1.5 (hNa v 1.5) by human b-subunits (hb).
The importance for modulation of hNa v 1.5 by hb-subunits is recently underpinned by several reports on mutations in hb-subunit genes leading to cardiac arrhythmias, likely caused by altered sodium channel expression and gating. The arrhythmic disorders associated with mutations in hb-subunit genes include: (i) SCN1B: cardiac conduction disease (CCD), atrial fibrillation (AF), and BrS; (ii) SCN2B: AF; (iii) SCN3B: BrS, idiopathic ventricular fibrillation (IVF), and AF; (iv) SCN4B: LQTS. 45 -47,124 -127 The effects of wild-type hb-subunits on hNa v 1.5 were assessed as controls in functional studies on mutant hb-subunit modulation of hNa v 1.5 in transfected cell lines. The general picture that emerges is that hb1 and its splice variant hb1B 124 increase hNa v 1.5 current density, and cause negative shifts in steady-state activation (gain-of-function) and inactivation (loss-of-function). 45, 124 Unfortunately, data on regulation of hNa v 1.5/hb1(B) plasma membrane expression in transfected cells were not provided. hb3 subunit reports were less straightforward. In only one out of three reports, 46, 125, 126 hNa v 1.5 current density was significantly increased when co-expressed with hb3. 125 In two studies, 46 45 or a negative shift in inactivation (loss-of-function) caused by hb4. 47 For hb4, co-immunoprecipitation with hNa v 1.5 was demonstrated from HEK293 cells. 47 Changes in plasma membrane expression of hNa v 1.5 protein were not determined in these studies. All mutated b-subunit proteins that associated with CCD, BrS, IVF, and AF caused a substantial reduction in Na v 1.5 channel availability typical for these cardiac channelopathies. Interestingly, the SCN3B L10P 125 and V54G 46 mutated hb3 subunits, associated with conduction defects, caused severe impairment of trafficking of hNa v 1.5 to the plasma membrane in TSA201 and HEK293 cells, respectively, whereas the SCN3B A130V 126 mutant, associated with lone AF, did not in HEK293 cells. In contrast, the LQTS L179F hb4 mutant, compared with wild-type hb4, caused destabilizing changes in inactivation resulting in a substantially increased persistent hNa v 1.5 current in HEK293 cells, resembling the effect of LQTS3 mutations in SCN5A that destabilize hNa v 1.5 inactivation. 47 
Conclusions and perspectives
In overview, it can be concluded that the compositional unravelling of the Na v 1.5 multiprotein complex has provided valuable insight into molecular modulators of the expression level, localization, and biophysical properties of Na v 1.5, but also that we are just at the beginning of understanding the complex mechanisms behind it. For example, membrane localization of Na v 1.5 in cardiomyocytes appears to be dependent on the presence of syntrophin (lateral membranes), SAP97 (intercalated discs), ankyrin-G (intercalated discs, T tubules), and a-actinin-2 (sarcomeric Z lines). Although these results indicate the existence of Na v 1.5 multiprotein complexes with different composition, they do not explain how these complexes are generated and targeted to their specific locations. In another example: the association studies with caveolin-3 suggested that Na v 1.5-based channels are locally stored in caveolae, from which they can be rapidly recruited upon b-adrenergic receptor stimulation. However, the origin and precise location of these reservoirs in the heart are presently not known. Despite these research questions, it can be expected that further investigation of the role of each presently known Na v 1.5 interacting partner and further expansion of the list of Na v 1.5 interacting partners will increase our knowledge of Na v 1.5 regulation considerably. The reviewed studies also indicate Na v 1.5 as a target for extensive post-translational modification (phosphorylation, glycosylation, S-nitrosylation, ubiquitination, methylation; 128 see also Figure 1 ), which may influence its expression, trafficking, turnover, and/or function. As for (de)phosphorylation, the kinases PKA, PKC, CaMKII, and Fyn as well as the phosphatase PTPH1 are presently known to modify Na v 1.5 at particular sites ( Figure 1 ), but regulation of Na v 1.5 by other kinases (and phosphatases) or at other phosphorylation sites is likely.
The inconsistent results obtained for CaMKII-mediated modulation of Na v 1.5 gating may very well originate from the use of different target phosphorylation sites in Na v 1.5 by CaMKII. Glycosylation of Na v 1.5, on the other hand, has also been implicated as modulator of its gating parameters. At present, little is known regarding the nature of the N-glycan chains present in Na v 1.5, the precise sites of glycosylation or whether alterations in these chains occur in cardiac disease. Therefore, elucidation of the nature, extent, and functional consequences of Na v 1.5 post-translational modifications in health and disease is considered a major future research aim. Such studies may benefit considerably from further insight into the structural details underlying voltage-sensing and -gating, as recently provided, for example, by the three-dimensional analysis of the voltage-dependent sodium channel of Arcobacter butzleri.
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Another intriguing and uncomprehended aspect is the identification of multiple transcripts encoding Na v 1.5 in the heart, some of which differ in their efficiency of translation or produce Na v 1.5 proteins with deviant functional properties. Investigation of the relative distribution and functional contribution of each transcript in the healthy and diseased heart should provide more information on their role in Na v 1.5 regulation.
